A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.-Reference-Cited by-同舟云学术

A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:TPS4144-TPS4144
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Abou-Alfa Ghassan K.¹,Chan Stephen Lam²,Furuse Junji³,Galle Peter R.⁴,Kelley Robin Kate⁵,Qin Shukui⁶,Armstrong Jon⁷,Darilay Annie⁸,Vlahovic Gordana⁹,Negro Alejandra¹⁰,Sangro Bruno¹¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY;

2. The Chinese University of Hong Kong, Shatin, Hong Kong;

3. Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan;

4. University Medical Center Mainz, Mainz, Germany;

5. University of California, San Francisco, CA;

6. People's Liberation Army Cancer Center, Nanjing, China;

7. AstraZeneca, Alderley Park, United Kingdom;

8. AstraZeneca, London, United Kingdom;

9. AstraZeneca, Gaithersburg, MD;

10. AstraZeneca, Gaithersburg, MD, US;

11. Clinica Universidad de Navarra, Navarra, Spain;